Envista Holdings Co. (NYSE:NVST) Receives $20.65 Average Target Price from Brokerages

Envista Holdings Co. (NYSE:NVST - Get Free Report) has earned an average rating of "Hold" from the sixteen brokerages that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $20.65.

Several equities analysts have commented on the stock. Piper Sandler lifted their target price on shares of Envista from $16.00 to $17.00 and gave the stock a "neutral" rating in a research report on Thursday, October 31st. Mizuho assumed coverage on shares of Envista in a research report on Wednesday. They set an "underperform" rating and a $20.00 target price on the stock. Evercore ISI lifted their target price on shares of Envista from $18.00 to $23.00 and gave the stock an "outperform" rating in a research report on Monday, September 23rd. Leerink Partners raised shares of Envista from an "underperform" rating to a "market perform" rating and lifted their target price for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Finally, Bank of America dropped their price objective on Envista from $22.00 to $19.00 and set a "buy" rating on the stock in a research note on Thursday, August 8th.

Envista Stock Down 2.4 %

NYSE NVST traded down $0.49 during trading hours on Thursday, hitting $20.08. The company's stock had a trading volume of 2,587,086 shares, compared to its average volume of 2,383,254. Envista has a 52 week low of $15.15 and a 52 week high of $25.64. The company has a market capitalization of $3.46 billion, a PE ratio of -2.58, a price-to-earnings-growth ratio of 3.06 and a beta of 1.31. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The company's 50-day simple moving average is $19.98 and its two-hundred day simple moving average is $18.36.

Envista (NYSE:NVST - Get Free Report) last posted its earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm had revenue of $601.00 million for the quarter, compared to analysts' expectations of $590.34 million. During the same quarter last year, the firm earned $0.43 EPS. The company's quarterly revenue was down 4.8% compared to the same quarter last year. Research analysts anticipate that Envista will post 0.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

Hedge funds and other institutional investors have recently bought and sold shares of the business. M&G Plc raised its holdings in Envista by 12.5% during the 2nd quarter. M&G Plc now owns 306,253 shares of the company's stock valued at $5,206,000 after acquiring an additional 33,923 shares during the period. Nuance Investments LLC raised its holdings in Envista by 47.2% during the 2nd quarter. Nuance Investments LLC now owns 7,038,313 shares of the company's stock valued at $117,048,000 after acquiring an additional 2,256,993 shares during the period. Sei Investments Co. raised its holdings in Envista by 20.4% during the 2nd quarter. Sei Investments Co. now owns 925,170 shares of the company's stock valued at $15,386,000 after acquiring an additional 157,048 shares during the period. WINTON GROUP Ltd bought a new position in shares of Envista in the second quarter worth $7,019,000. Finally, Raymond James & Associates increased its holdings in shares of Envista by 22.6% in the second quarter. Raymond James & Associates now owns 1,032,350 shares of the company's stock worth $17,168,000 after purchasing an additional 190,240 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.